Ascendis Pharma A/S (NASDAQ:ASND) – Research analysts at Wedbush lowered their Q1 2019 earnings per share (EPS) estimates for Ascendis Pharma A/S in a research note issued to investors on Monday, April 8th. Wedbush analyst L. Moussatos now expects that the biotechnology company will earn ($1.08) per share for the quarter, down from their prior forecast of ($1.04). Wedbush currently has a “Buy” rating and a $219.00 target price on the stock. Wedbush also issued estimates for Ascendis Pharma A/S’s Q2 2019 earnings at ($1.13) EPS, Q3 2019 earnings at ($1.23) EPS, Q4 2019 earnings at ($1.23) EPS, FY2019 earnings at ($4.68) EPS, FY2020 earnings at ($5.08) EPS, FY2021 earnings at ($2.65) EPS and FY2022 earnings at $3.28 EPS.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Wednesday, April 3rd. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.17) by $0.30. The firm had revenue of $12.00 million for the quarter. Ascendis Pharma A/S had a negative return on equity of 40.86% and a negative net margin of 1,275.08%.

ASND has been the topic of a number of other reports. BidaskClub upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Thursday, January 10th. Leerink Swann raised Ascendis Pharma A/S from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $73.00 to $90.00 in a research report on Thursday, January 24th. Zacks Investment Research lowered Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th. Canaccord Genuity upped their target price on Ascendis Pharma A/S from $132.00 to $133.00 and gave the stock a “buy” rating in a research report on Friday, April 5th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $185.00 target price on shares of Ascendis Pharma A/S in a research report on Monday, March 18th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $135.56.

Ascendis Pharma A/S stock opened at $120.60 on Thursday. The company has a market cap of $5.01 billion, a price-to-earnings ratio of -32.25 and a beta of 1.01. Ascendis Pharma A/S has a 52-week low of $53.21 and a 52-week high of $131.76.

Several large investors have recently modified their holdings of the company. Deutsche Bank AG raised its position in shares of Ascendis Pharma A/S by 27.3% during the fourth quarter. Deutsche Bank AG now owns 120,287 shares of the biotechnology company’s stock worth $7,535,000 after purchasing an additional 25,782 shares during the period. Geode Capital Management LLC raised its position in shares of Ascendis Pharma A/S by 12.7% during the fourth quarter. Geode Capital Management LLC now owns 30,743 shares of the biotechnology company’s stock worth $1,926,000 after purchasing an additional 3,459 shares during the period. FMR LLC raised its position in shares of Ascendis Pharma A/S by 1.2% during the fourth quarter. FMR LLC now owns 4,203,246 shares of the biotechnology company’s stock worth $263,333,000 after purchasing an additional 50,984 shares during the period. Squarepoint Ops LLC acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter worth approximately $204,000. Finally, D. E. Shaw & Co. Inc. raised its position in shares of Ascendis Pharma A/S by 14.6% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 46,181 shares of the biotechnology company’s stock worth $2,893,000 after purchasing an additional 5,881 shares during the period. 95.46% of the stock is currently owned by institutional investors.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Featured Story: Mutual Funds

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.